Table 1 Clinical data of SLE patients at the time of enrollment

Age (Y)

31.24 ± 7.41

18–50

Sex (F/M)

72 (90%)/8 (10%)

 Duration of HCQ therapy (years)

0.3–15

 _{Daily dose mg/kg}

4.89± 1.01

2.2–7.1

 Cumulative dose (g)

713.67 ± 498.75

36.5 ± 2190

 SLEDAI

0–25

 BCVA

0.85 ± 0.30

0.1–1/0.16–1

 ESR (mm/h)

5–140

 ANA positive (IU/ml)

75 (93.8%)

 Ant-DNA positive (U/ml)

49 (61.3%

 Normal

77 (96.2%)

 Bull’s eye

3 (3.8%)

 Normal

75 (93.8%)

 Abnormal (bull’s eye/RPE)

5 (6.3%)

 Normal

68 (85.0%)

 Significant change

9 (11.3%)

 Non-reliable

3 (33.8%)